New technologies emerging from the Human Genome Project and the rapidly expanding direct-to-consumer DNA testing have provided a challenging environment for the entry of pharmacogenomics into clinical ...

Tools such as genome resequencing and genome-wide association studies have recently been used to uncover a number of variants that affect drug toxicity and efficacy, as well as potential drug targets.

Pharmacogenomics (PGx) testing is a powerful tool in the evolution of personalized medicine. However, for its full potential to be realized, labs must do more than just offer a scientifically sound ...

As part of this initiative, PGxAI will roll out a suite of pharmacogenomic reports on Sequencing.com that provide personalized drug implications based on an individual’s genomic data. They directly ...

In a report recently published in the American Journal of Health-System Pharmacy, the Ochsner Health system delves into the multifaceted implementation of pharmacogenomics-a rapidly evolving field ...

OXFORD, England--(BUSINESS WIRE)--Oxford Nanopore Technologies (Oxford Nanopore) today announced the launch of a new Pharmacogenomics (PGx) Beta Program to advance personalised medicine, combining ...

Pharmacogenomics (PGx) is a subset of precision medicine that focuses on the genetics behind different pharmaceutical interactions, toxicities, and efficacies. PGx improves drug discovery and ...

Depression affects millions globally, presenting a significant challenge for effective treatment. Traditional approaches often rely on trial and error to find ...